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Commentary The CC genotype of the ERCC1 C118T single-nucleotide polymorphism impacts positively on the efficacy of NB-UVB therapy for vitiligo
Vitiligo is a common depigmenting skin disease with a prevalence of 1-2%. 1 Although the exact aetiology and detailed pathogenesis of vitiligo is not fully understood, autoreactive T cell responses against melanocytes are clearly involved in the development of the disease.
2,3
Of several immunosuppressive treatments, narrow-band ultraviolet B (NB-UVB) now represents the phototherapy of choice for inducing repigmentation in patients with generalised vitiligo where depigmented areas affect multiple sites or large areas of the body. Indeed, more than 75% repigmentation has been achieved in over 50% of patients. 4, 5 It is also useful for halting the progression of currently active vitiligo; stabilisation of the disease was evident in 80% of treated patients. 5 Comparative studies have indicated also the superior efficacy and better safety profile of NB-UVB over psoralen with UVA. 6, 7 As yet, the precise mechanism of action of NB-UVB in repigmenting vitiligo lesions is unknown. However, NB-UVB can activate the release from keratinocytes of endothelin-1 and basic fibroblast growth factor, which stimulate melanocyte, and can stimulate the expression of focal adhesion kinase and matrix metalloproteinases, which may enhance melanocyte migration from the outer root sheath of the hair follicle into the epidermis. 8 In addition, during NB-UVB irradiation, skin-infiltrating T cells are induced to apoptose due to the accumulation of DNA damage in the form of cyclobutane pyrimidine dimers. 9 Repair of such damaged DNA is managed via the nucleotide excision repair (NER) pathway and, interestingly, single-nucleotide polymorphisms of the DNA repair gene APE1 have been associated with susceptibility to vitiligo. 
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